Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,439 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,350)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04679506 | the Efficacy and Safety of CLAE in R/R T-ALL/LBL | unknown | — | 50 | Peking University Third HospitalOTHER | 0 | Dec 22, 2020 | clinicaltrials |
| NCT04677231 | Evaluation of Long-term Health Status and Quality of Life in Adult Survivors With Philadelphia-negative Acute Lymphoblastic Leukemia/Lymphoma Treated With an Intensive Pediatric or Pediatric-inspired Protocol(EQUAALL01) | unknown | — | 300 | Assistance Publique - Hôpitaux de ParisOTHER |
| 0 |
| Dec 21, 2020 |
| clinicaltrials |
| NCT04254640 | Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML | unknown | Phase 2 | 34 | Sun Yat-sen UniversityOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT04336501 | Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation | unknown | N/A | 20 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Dec 17, 2020 | clinicaltrials |
| NCT03135054 | Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD | unknown | Phase 2 | 40 | The University of Hong KongOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT04100070 | Intensive Versus Standard One Year Monitoring on Glycaemic Control After Initiating CSII in Children With DT1. DEEP Study(DEEP) | unknown | N/A | 320 | ISIS Diabete ServiceOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04117854 | Spinal Cord Injury in the Pediatric Population - an International Multicenter Study(SINpedSCI) | unknown | — | 30 | Sunnaas Rehabilitation HospitalOTHER | 8 | Dec 2, 2020 | clinicaltrials |
| NCT03981510 | Comparison of Gastrointestinal Motility in Healthy Children and Children With Constipation | unknown | N/A | 80 | University of AarhusOTHER | 1 | Nov 25, 2020 | clinicaltrials |
| NCT04640064 | Hb A1C Pre and Post Confinement in Latin American Children With Type 1 Diabetes: Dulce Study Group | unknown | — | 500 | Hospital General PuyoOTHER_GOV | 1 | Nov 23, 2020 | clinicaltrials |
| NCT04000698 | Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias | unknown | Phase 3 | 25 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT04636918 | Ikervis for DED Due to GVHD Post Allo-HSCT(Ikervis) | unknown | Phase 4 | 40 | Singapore Eye Research InstituteOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT04516551 | Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT | unknown | Phase 1 | 18 | Xinqiao Hospital of ChongqingOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT04626726 | Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation | unknown | Early Phase 1 | 50 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04626765 | CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia | unknown | Early Phase 1 | 50 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04620655 | RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL | unknown | N/A | 24 | Min XiangOTHER | 1 | Nov 9, 2020 | clinicaltrials |
| NCT03559439 | CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies | unknown | Phase 1 | 9 | Shanghai Tong Ren HospitalOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT02772198 | T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies | unknown | Phase 1 / Phase 2 | 300 | Sheba Medical CenterOTHER_GOV | 1 | Nov 3, 2020 | clinicaltrials |
| NCT02172365 | Allogeneic SCT for CML, TKI Failure After TKI Failure | unknown | — | 350 | University Health Network, TorontoOTHER | 1 | Nov 2, 2020 | clinicaltrials |
| NCT04610125 | Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children | unknown | N/A | 30 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT01064557 | "AIDA" Protocol (LAP 0493) | unknown | N/A | 1,068 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 5 | Oct 14, 2020 | clinicaltrials |
| NCT01064570 | AIDA 2000 Guidelines | unknown | Phase 2 | 600 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT03083054 | Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 5 | University of Campinas, BrazilOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT03302403 | Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors | unknown | N/A | 18 | Kang YUOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT04578847 | A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)(READIT) | unknown | Phase 2 | 100 | National Research Center for Hematology, RussiaNETWORK | 1 | Oct 8, 2020 | clinicaltrials |
| NCT03327285 | C-CAR011 Treatment in Subjects With ALL After HSCT | unknown | N/A | 40 | Peking University People's HospitalOTHER | 1 | Oct 1, 2020 | clinicaltrials |
| NCT03759899 | hAECs Are Preliminarily Applied in Allogeneic Hematopoietic Stem Cell Transplantation | unknown | — | 30 | Peking University People's HospitalOTHER | 1 | Oct 1, 2020 | clinicaltrials |
| NCT04221971 | NK Cell Infusion for Patients With Acute Myeloid Leukemia | unknown | Phase 1 | 10 | Peking University People's HospitalOTHER | 1 | Oct 1, 2020 | clinicaltrials |
| NCT04298502 | The Molecular Mechanism of CMV-driven NKG2C+NK Cell Expansion in Human | unknown | — | 40 | Peking University People's HospitalOTHER | 1 | Oct 1, 2020 | clinicaltrials |
| NCT04004637 | CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia | unknown | Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Sep 28, 2020 | clinicaltrials |
| NCT04554381 | Assesment of JL1 Expression in Acute Leukemia | unknown | Phase 1 | 50 | Assiut UniversityOTHER | 0 | Sep 18, 2020 | clinicaltrials |
| NCT03756675 | Haploidentical Peripheral Blood Stem Cell Transplantation for Acute Leukemia | unknown | — | 45 | Peking University People's HospitalOTHER | 1 | Sep 17, 2020 | clinicaltrials |
| NCT04373395 | Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML) | unknown | N/A | 65 | Zhejiang UniversityOTHER | 1 | Sep 16, 2020 | clinicaltrials |
| NCT04454580 | Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy | unknown | — | 15 | Ospedale Maggiore Di TriesteOTHER | 1 | Sep 16, 2020 | clinicaltrials |
| NCT02381379 | Malaysia Stop Tyrosine Kinase Inhibitor Trial(MSIT) | unknown | Phase 3 | 118 | Ministry of Health, MalaysiaOTHER_GOV | 1 | Sep 14, 2020 | clinicaltrials |
| NCT04546893 | Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia | unknown | N/A | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Sep 14, 2020 | clinicaltrials |
| NCT04546906 | Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia | unknown | N/A | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Sep 14, 2020 | clinicaltrials |
| NCT04544878 | Pediatric Intensive Care and COVID-19(CLOVIS) | unknown | — | 100 | Bicetre HospitalOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT04541277 | Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy | unknown | Phase 2 | 55 | Chinese PLA General HospitalOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT04240600 | Effect of a Hyperproteic Hyperenergetic Enteral Formula on Body Composition and VEGF in AML During Hospital Stay(HEMVEF) | unknown | N/A | 74 | Hospital General de MexicoOTHER_GOV | 1 | Sep 3, 2020 | clinicaltrials |
| NCT04534634 | Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL） | unknown | Phase 2 | 60 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT04532268 | A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL | unknown | Early Phase 1 | 72 | Zhejiang UniversityOTHER | 1 | Aug 31, 2020 | clinicaltrials |
| NCT04519632 | Paediatric Palliative Care Pain Management in the Community(PARAMOUNT) | unknown | — | 68 | University of SouthamptonOTHER | 1 | Aug 19, 2020 | clinicaltrials |
| NCT04517175 | Could Ki-67 be Used as a Diagnostic or Prognostic Marker in Hemato-oncological Diagnostics? | unknown | — | 300 | Maastricht UniversityOTHER | 0 | Aug 18, 2020 | clinicaltrials |
| NCT04497701 | Evaluate the Efficacy and Safety of the Prophylactic Use of PEG-rhG-CSF in Children With Hematological Malignancies | unknown | N/A | 139 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 4, 2020 | clinicaltrials |
| NCT04496011 | Effect of the Cycloergometer in Patients Undergoing Hematopoietic Stem Cell Transplantation | unknown | N/A | 30 | Federal University of Health Science of Porto AlegreOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT04209712 | Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease | unknown | Early Phase 1 | 6 | Shanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaINDUSTRY | 1 | Jul 29, 2020 | clinicaltrials |
| NCT04488237 | Vitamin D and Methotrexate Adverse Effects | unknown | — | 50 | Assiut UniversityOTHER | 0 | Jul 27, 2020 | clinicaltrials |
| NCT02735291 | Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia(EECNTL) | unknown | N/A | 72 | Sinobioway Cell Therapy Co., Ltd.INDUSTRY | 1 | Jul 15, 2020 | clinicaltrials |
| NCT04288739 | Immunophenotyping and Xist Gene in AML(Xist) | unknown | — | 65 | Assiut UniversityOTHER | 1 | Jul 9, 2020 | clinicaltrials |
| NCT04450784 | ObServatory Children Acute RElated Therapy Leukemia(OSCARE) | unknown | — | 40 | University Hospital, BordeauxOTHER | 0 | Jul 1, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Dec 22, 2020source: clinicaltrials